<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nelson GW</submitter><funding>Frederick National Laboratory for Cancer Research</funding><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>e0028124</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11338073</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>98(8)</volume><pubmed_abstract>&lt;i>HLA&lt;/i> class I variation has the strongest effect genome-wide on outcome after HIV infection, and as such, an understanding of the impact of &lt;i>HLA&lt;/i> polymorphism on response to HIV vaccination may inform vaccine design. We sought &lt;i>HLA&lt;/i> associations with HIV-directed immunogenicity in the phase 1/2a APPROACH vaccine trial, which tested vaccine regimens containing mosaic inserts in Ad26 and MVA vectors, with or without a trimeric gp140 protein. While there were no &lt;i>HLA&lt;/i> allelic associations with the overall cellular immune response to the vaccine assessed by ELISpot (Gag, Pol, and Env combined), significant associations with differential response to Gag compared to Env antigens were observed. Notably, &lt;i>HLA&lt;/i> class I alleles known to associate with disease susceptibility </pubmed_abstract><journal>Journal of virology</journal><pubmed_title>Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.</pubmed_title><pmcid>PMC11338073</pmcid><funding_grant_id>U01 HL146240</funding_grant_id><funding_grant_id>UM1 AI068636</funding_grant_id><funding_grant_id>75N91019D00024</funding_grant_id><funding_grant_id>UM1 AI068618</funding_grant_id><pubmed_authors>Stieh D</pubmed_authors><pubmed_authors>Pau MG</pubmed_authors><pubmed_authors>Barouch DH</pubmed_authors><pubmed_authors>Lavreys L</pubmed_authors><pubmed_authors>DeRosa SC</pubmed_authors><pubmed_authors>Carrington M</pubmed_authors><pubmed_authors>Nelson GW</pubmed_authors><pubmed_authors>Yuki Y</pubmed_authors><pubmed_authors>Kirk GD</pubmed_authors><pubmed_authors>Wolinsky S</pubmed_authors><pubmed_authors>Tomaka F</pubmed_authors><pubmed_authors>Walker B</pubmed_authors><pubmed_authors>van Duijn J</pubmed_authors><pubmed_authors>Haas DW</pubmed_authors><pubmed_authors>Michael NL</pubmed_authors><pubmed_authors>McElrath MJ</pubmed_authors><pubmed_authors>Deeks SG</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.</name><description>&lt;i>HLA&lt;/i> class I variation has the strongest effect genome-wide on outcome after HIV infection, and as such, an understanding of the impact of &lt;i>HLA&lt;/i> polymorphism on response to HIV vaccination may inform vaccine design. We sought &lt;i>HLA&lt;/i> associations with HIV-directed immunogenicity in the phase 1/2a APPROACH vaccine trial, which tested vaccine regimens containing mosaic inserts in Ad26 and MVA vectors, with or without a trimeric gp140 protein. While there were no &lt;i>HLA&lt;/i> allelic associations with the overall cellular immune response to the vaccine assessed by ELISpot (Gag, Pol, and Env combined), significant associations with differential response to Gag compared to Env antigens were observed. Notably, &lt;i>HLA&lt;/i> class I alleles known to associate with disease susceptibility </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2026-06-02T23:30:31.024Z</modification><creation>2025-04-04T03:10:41.137Z</creation></dates><accession>S-EPMC11338073</accession><cross_references><pubmed>39046263</pubmed><doi>10.1128/jvi.00281-24</doi></cross_references></HashMap>